In summary, in addition to mammary, urothelial, thyroid, and apocrine gland sac carcinomas, we demonstrated that HER2 is overexpressed in a large proportion of intestinal, rectal and urothelial carcinomas, as well as in a subset of oral and cutaneous squamous cell carcinomas. This evidence concerns the gene ERBB2 and urothelial carcinoma.